Faze Med­i­cines launch­es with $81M Se­ries A, Al­ny­lam vet head­ing sci­ence in play at bio­mol­e­c­u­lar con­den­sates

Once most­ly un­known to the larg­er sci­en­tif­ic world, the field of bio­mol­e­c­u­lar con­den­sates — cel­lu­lar struc­tures that could have big im­pli­ca­tions on neu­rode­gen­er­a­tive re­search — has seen a rush of in­vestor cash in the past two years. Now, a third biotech is tak­ing a swing at the field with a siz­able ini­tial fund­ing round to get go­ing.

Faze Med­i­cines, a Third Rock-backed biotech look­ing to de­vel­op med­i­cines tar­get­ing neu­rode­gen­er­a­tive dis­eases and po­ten­tial­ly even more ther­a­peu­tic ar­eas, launched Thurs­day with an $81 mil­lion Se­ries A round and Al­ny­lam vet­er­an Rachel Mey­ers head­ing up the sci­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER